Source: SELLAS Life Sciences Group & reported by http://www.prnewswire.com/
ZUG, Switzerland and NEW YORK, May 24, 2016 /PRNewswire/ -- SELLAS™ Life Sciences Group (SELLAS™), a development-stage biopharmaceutical company with its main focus on developing innovative products to treat cancer, today announced that results from a Phase 2 trial of the Company's WT1 cancer vaccine, galinpepimut-S, in patients with acute myeloid leukemia (AML) will be presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO), being held in Chicago, IL, June 3-7, 2016. SELLAS™ also will present a poster detailing Phase 2 results of its WT1 cancer vaccine for the treatment of patients with malignant pleural mesothelioma (MPM). In addition, SELLAS™ announced today that ZELTHERVA has been formally accepted by the U.S. Food and Drug Administration's Center for Biologics Evaluation and Research as the proprietary name for SELLAS™'s cancer vaccine. SELLAS™'s WT1 vaccine is a late clinical-stage cancer immunotherapy being developed to target hematologic cancers and solid tumors, including AML, MPM, multiple myeloma, ovarian cancer, and multiple other cancers. Based on the results of its mid-stage clinical program, SELLAS™ expects to begin a pivotal Phase 3 trial of its WT1 vaccine in AML patients and a pivotal Phase 2b/3 trial of its WT1 vaccine in patients with MPM later this year.
About the Phase 1 and 2 Trials in AML: Phase 1 and Phase 2 trials studied the WT1 analog peptide vaccine in combination with Montanide-adjuvant + GM-CSF in patients with AML who were in first complete response and completed any planned post-remission therapy. Altogether, 31 patients were enrolled in the two studies at Memorial Sloan Kettering Cancer Center. The WT1 vaccine was also provided to the Moffitt Cancer Center for an independent Phase 2 study in AML and myelodysplastic syndrome (MDS) patients (N=10) in second remission (CR2).
Read more: http://www.prnewswire.com/news-releases/sellas-life-sciences-announces-upcoming-presentation-of-phase-2-clinical-results-for-wt1-cancer-vaccine-at-the-2016-asco-annual-meeting-300273378.html